Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
67 results about "Cervix Intraepithelial Neoplasia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is the abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer.
DFMO for the treatment or prevention of cervical intraepithelial neoplasia
InactiveUS6166079AReduce riskInhibit transformationBiocidePeptide/protein ingredientsCytotoxicityCervical intraepithelial neoplasia
Methods for treating, preventing, controlling the growth of and / or reducing the risk of developing cervical cancer, particularly in patients with cervical intraepithelial neoplasia are provided employing pharmaceutically acceptable preparations of DFMO. Methods for treating a patient having cervical intraepithelial neoplasia, which methods comprise administering DFMO alone or in combination with a cytotoxic or cytostatic agent, are also provided.
Owner:TEXAS SYST UNIV OF BOARD OF REGENTS THE +1
Computerized image analysis for acetic acid induced Cervical Intraepithelial Neoplasia
InactiveUS20090034824A1High strengthIncrease contrastImage enhancementImage analysisAcetic acidMedicine
A method for differentiating cancerous lesions from surrounding tissue, which includes extracting an opacity parameter from acetowhite regions of pre acetic acid and post acetic acid images of a cervix.
Owner:STI MEDICAL SYST
Methods and apparatus for characterization of tissue samples
InactiveUS7309867B2High diagnostic sensitivityStrong specificityDiagnostics using lightPhotometryStatistical classificationMetaplasia
The invention provides methods for determining the probability that a given region of a tissue sample contains tissue of a given category, such as CIN 1 (cervical intraepithelial neoplasia, grade 1), CIN 2 / 3 (cervical intraepithelial neoplasia grades 2 and / or 3), normal squamous, normal columnar, and metaplasia, for example. The invention provides increased diagnostic accuracy by combining a plurality of statistical classification techniques. Furthermore, in one embodiment, the invention comprises combining one or more statistical techniques with one or more non-statistical classification techniques.
Owner:LUMA IMAGING CORP
Chemoprevention and treatment of cervical or vaginal neoplasia
InactiveUS6399645B1Inhibit progressBiocideAnimal repellantsViral diseaseCervical intraepithelial neoplasia
The invention relates to non-surgical methods for treating cervical or vaginal neoplasia including cervical intraepithelial neoplasia, intraepithelial neoplasia, vulvar intraepithelial neoplasia and ano-genital warts. The treatment, which utilizes an effective amount of indole-3-carbinol and / or diindolylmethane, is effective whether or not the patient is also infected with human papillomavirus, the most common sexually transmitted viral disease in the United States and a known risk factor for both cervical intraepithelial neoplasia and cervical cancer.
Owner:BELL MARIA +1
Methods for detecting papillomavirus DNA in blood plasma and serum
InactiveUS7183053B2Assess prognosisAntibody mimetics/scaffoldsMicrobiological testing/measurementDiseaseAlphapapillomavirus
This invention relates to the detection of extracellular papillomavirus DNA in blood plasma or serum from a human or animal. In particular, the invention relates to the detection, identification, evaluation, or monitoring of neoplastic, premalignant or malignant disease associated with a papillomavirus. The invention thereby provides methods for the identification of individuals at risk for, or having, cervical dysplasia, cervical intraepithelial neoplasia, or cervical cancer.
Owner:PENN STATE RES FOUND
Use of red nocardial cell wall skeleton in preparation of medicine
InactiveCN101073583AImprove correspondenceAvoid bodily adverse reactionsBacteria material medical ingredientsPharmaceutical delivery mechanismGynecologyCervical intraepithelial neoplasia
Owner:LIAONING GREATEST BIO-PHARM CO LTD
Method for detecting carcinomas in a solubilized cervical body sample
ActiveUS7306926B2Biological material analysisPeptide preparation methodsCervical intraepithelial neoplasiaMultiple Tumor Suppressor-1
The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a solubilized body sample. The present invention is particularly directed to a method for detecting cervical carcinomas, cervical intraepithelial neoplasias, or cervical carcinomas in-situ from a solubilized cervical body sample of a human subject, by solubilizing the cervical body sample in a lysis buffer, and determining the overexpression of cyclin dependent kinase inhibitor p16 in the solubilized cervical sample. The invention also concerns a test kit usable for this purpose as well as an in-vitro diagnostic device.
Owner:VENTANA MEDICAL SYST INC
Methods and compositions relating to HPV-associated pre-cancerous and cancerous growths, including CIN
InactiveUS7410758B2Reduce riskImproved prognosisPeptide/protein ingredientsMicrobiological testing/measurementCervical intraepithelial neoplasiaOncology
The present invention concerns the use of E6 and / or E7 peptides from human papilloma virus (HPV) to evaluate a cell-mediated response in a patient infected with HPV to determine the prognosis for that patient with respect to the development or recurrence of pre-cancerous or cancerous growths, including cervical intraepithelial neoplasia (CIN).
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Anti-HPV (human papillomavirus) gel dressing and preparation method thereof
ActiveCN104491838AGood storage stabilityEasy to storePowder deliveryPeptide/protein ingredientsDiseaseTreatment effect
The invention discloses an anti-HPV (human papillomavirus) gel dressing and a preparation method thereof and particularly relates to application of anti-HPV gel dressing in prevention and treatment of HPV infection and other diseases. The anti-HPV gel dressing mainly comprises anti-HPV freeze-dried powder and a dissolving solution, wherein the anti-HPV freeze-dried powder comprises the following components: tea acidic protein AP, isomaltooligosacharide, a freeze-drying protective additive and a bactericide / fungistat; the dissolving solution comprises the following components: water, phosphate, glycerin and mint oil. The anti-HPV gel dressing prepared by virtue of the preparation method is not greasy, can absorb tissue percolate, does not easily flow out and impede the normal functions of mucous membranes, can be used for effectively treating genital virus infection and preventing cervical cancer and penile cancer and has remarkable treatment effects to the diseases such as cervical intraepithelial neoplasia (CIN) and chronic cervicitis caused by virus infection.
Owner:海南森瑞谱生命科学药业股份有限公司
Application of miRNA marker in preparation of cervical intraepithelial neoplasia agent for screening folic acid deficiency populations
InactiveCN106939333AMicrobiological testing/measurementDNA/RNA fragmentationCervical tissueCervical intraepithelial neoplasia
The invention relates to the fields of genetic engineering and clinical medicine science, and concretely relates to an application of an miRNA marker in the preparation of a cervical intraepithelial neoplasia agent for screening folic acid deficiency populations. The folic acid concentration which is not more than 10 nmol / L is judged as folic acid deficiency, and the miRNA marker comprises the following fourteen miRNAs: miR-10a, miR-375, miR-23a, miR-18a, miR-6774, miR-21, miR-3613, miR-4730, miR-1247, miR-3607, miR-224, miR-30a, miR-30c and miR-196b. A reagent or a kit can be used for inspecting the expression condition of the 14 miRNAs in cervical tissues of folic acid deficiency patients in order to analyze the CIN and cervical cancer suffering risk of like populations.
Owner:THE SECOND HOSPITAL OF SHANXI MEDICAL UNIV
Photonic probe apparatus with integrated tissue marking facility
ActiveUS20160066979A1Easy to classifySimple procedureMedical imagingDiagnostics using spectroscopyPhotonicsRadiology
The invention relates to a photonic probe apparatus and a method for probing tissue to detect and mark biological tissue with cancerous or precancerous states. The apparatus involves a probe for illuminating tissue and collecting light from an illuminated tissue region through the probe, a unit for analyzing collected light to determine whether a threshold measure of probability of a cancerous or precancerous lesion in the probed tissue region in contact with the probe is exceeded, and an integrated tissue marking facility which can be activated to mark the probed tissue region through the probe when the threshold measure is exceeded. The photonic probe apparatus and the method are especially suitable for probing regions in squamous and columnar epithelia to detect and mark regions with cervical cancer or cervical intraepithelial neoplasia (CIN).
Owner:KONINKLJIJKE PHILIPS NV
Method for knocking out HPV (human papilloma virus) E6E7 oncogene by use of TALEN (transcription activator-like effector nuclease)
The invention relates to the field of gene therapy and discloses a fixed-point knockout system for high-risk HPV (human papilloma virus) E6E7 gene, namely targeted cutting of TALENs (transcription activator-like effector nucleases) of HPV E6E7 gene, wherein a TALENs expression vector of the target specific site is designed according to the high-risk HPV E6E7 gene sequence, and the HPV E6E7 gene sequence in the cells are cut in a targeted manner so as to knock out the target gene and induce the apoptosis increase and proliferation inhibition of corresponding subtype cells while the TALENs do not act on the HPV positive or HPV negative cells of other subtypes. By transfecting the TALEN expression vector in a subcutaneous tumor model of HPV positive cervical cancer cells, the growth of subcutaneous tumor can be obviously inhibited, and the tumor weight is reduced. According to the method for targeted knockout of high-risk HPV E6E7 gene using TALEN provided by the invention, the virus oncogene can be efficiently broken on the DNA level so as to cause apoptosis and proliferation inhibition of the HPV infected cells, and the method is of tremendous therapeutic value on HPV infection related diseases and particularly precancerous lesions such as cervical intraepithelial neoplasias.
Owner:武汉雅马生物工程有限公司
Cervices intraepithelial neoplasia model and model establishing method
InactiveCN101125102ARich sourcesExplore the mechanism of carcinogenesisDiagnosticsSurgeryHuman tumorImmunodeficiency
The present invention relates to a cervical intraepithelial neoplasia model and the method of establishing model, which is characterized in that the cervical intraepithelial neoplasia tissue is embedded in the immunodeficiency mice to establish cervical intraepithelial neoplasia model. The method of establishing model is characterized in that the cervical intraepithelial neoplasia tissue is respectively taken from the biopsy under the vaginoscope and the tissues which are confirmed by the department of pathology and is inoculated subcutaneously in the back of the mice; the immunodeficiency mice of the present invention can overcome the xenoislet immune rejection reaction and receive the transplantation of the human tumor tissues, the tissue model after the transplantation has significant and stable character, short observation period and greater clinical reference significance of the experimental results. The present invention can explore the mechanism of the carcinogenesis of cervical carcinoma by outcome of the pathological process of CIN I, CIN II and CIN III animal models. Furthermore, by observing the period of the outcome of the cervical intraepithelial neoplasia tissue of the animal model, the present invention provides the feasible clinical animal experimental model for reversing the malignant transformation of the CIN I and CIN II lesion tissues.
Owner:ANHUI PROVINCIAL HOSPITAL
PAP (pokeweed antiviral protein) freeze-dried powder compounding agent and preparation method of thereof
ActiveCN104353058AKill and clear infectionPrevent cervical cancerOrganic active ingredientsPowder deliveryDiseasePokeweed antiviral protein
The invention discloses a PAP (pokeweed antiviral protein) freeze-dried powder compounding agent as well as a preparation method and an application thereof, in particular to an application in treatment and prevention of HPV (human papillomavirus) virus infection and related diseases. The PAP freeze-dried powder compounding agent comprises PAP freeze-dried powder and a dissolution liquid, wherein components of the PAP freeze-dried powder comprise PAP, phyto-laccasaponin, polysaccharide and cordycepin; and components of the dissolution liquid comprise water, ethanol, phosphate, glycerol, menthol and preservative. The compounding agent prepared by taking PAP as a main component can effectively treat HPV infection, prevent cervical cancer and penis cancer, has a remarkable curative effect on diseases such as CIN (cervical intraepithelial neoplasia), cervical erosion, cervical polyp, cervical hypertrophy and like caused by HPV infection, and has good clinic application prospect.
Owner:海南森瑞谱生命科学药业股份有限公司
Methods and compositions relating to HPV-associated pre-cancerous and cancerous growths, including CIN
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Topical treatment for cervical intraepithelial neoplasia
InactiveUS20160279083A1Increase moistureImprove smoothnessMedical devicesAnhydride/acid/halide active ingredientsPullulanCervix
Physiologically acceptable films for use in the treatment cervical intraepithelial neoplasia are disclosed. The films include a water soluble film-forming polymer such as pullulan, and therapeutically effective amounts of chemexfoliation agents. Devices adapted to introduce these films to the cervix are disclosed, as well as various combinations of devices and films sufficient to comprise a kit to enable treatment of CIN 1, 2, and 3.
Owner:MOEIN SUDABEH DR +1
Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer
ActiveUS20120202872A1High and low rate of survivalHigh/low rate of survivalOrganic active ingredientsSugar derivativesCervix Intraepithelial NeoplasiaPathology
The invention provides methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer. The methods comprise the step of determining the expression levels or genetic status of specific miRNAs.
Owner:CAPITALBIO CORP +1
Double-dyeing kit for cervical intraepithelial neoplasia grading assisted diagnosis, and applications thereof
InactiveCN104792988AHigh sensitivityImprove featuresMaterial analysisTrue positive rateCervical intraepithelial neoplasia
The present invention discloses a double-dyeing kit for cervical intraepithelial neoplasia grading assisted diagnosis, and applications thereof, wherein the double-dyeing kit comprises an immunohistochemisty marker first antibody, and the immunohistochemisty marker first antibody is a mixed antibody reagent comprising Stathmin antibody and MCM2 antibody. With the application of the double-dyeing kit in the cervical intraepithelial neoplasia grading assisted diagnosis, the two immunohistochemisty markers are adopted as the mixed antibody so as to increase the sensitivity and the specificity of the CIN grading and accurately identifying the CIN grading; and the readability and the accuracy of the film reading are increased, the detection cost is reduced, and the operation steps are reduced.
Owner:GUANGZHOU LBP MEDICINE SCI & TECH
Method for screening candidate plasma protein markers by cervical carcinoma specificity difference expression
InactiveCN103409501AProven reliabilityProof of accuracyMicrobiological testing/measurementProtein markersScreening method
The invention discloses a method for screening candidate plasma protein markers by cervical carcinoma specificity difference expression. The method comprises the following steps: (1)collecting clinical specimens, and preparing tissue RNA (Ribonucleic Acid); (2) analyzing a uyghur woman cervical carcinoma and precancerous lesion tissue RNA high-density human gene expression profile chip; and (3) carrying out semiquantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction) analysis on cervical carcinoma specificity difference expression candidate genes. The method disclosed by the invention discovers that the expression level of mRNA (Messenger RNA) encoded by most of candidate genes has outstanding difference between CSCC (Cervical Sqamous Cell Carcinoma) (or CIN (Cervical Intraepithelial Neoplasia)) and NC tissues through semiquantitative PCR (Polymerase Chain Reaction) screening identification and proves the reliability and sensitivity of the analytical data of the gene chip.
Owner:XINJIANG MEDICAL UNIV
Methods and Systems for Predicting Whether a Subject Has a Cervical Intraepithelial Neoplasia (CIN) Lesion from a Suspension Sample of Cervical Cells
ActiveUS20150259756A1Bioreactor/fermenter combinationsBiological substance pretreatmentsCervical cellCervical cancer screening
Owner:INCELLDX
Antigen for detecting human papillomavirus antibody and related immunoassay kit
ActiveCN106632617AHigh sensitivityRelieve painVirus peptidesBiological material analysisOncogene ProteinsCervical intraepithelial neoplasia
Owner:ATTOGEN BIOMEDICAL SUZHOU INC
Method for knockout of human papillomavirus E6E7 gene by zinc finger nucleases
ActiveCN104404076ANo knockout effectPromote proliferation inhibitionHydrolasesFermentationDiseaseViral Oncogene
Relating to the field of gene therapy, the invention provides a method for knockout of a high-risk human papillomavirus (HPV) E6E7 gene by zinc finger nucleases (ZFNs). According to a high-risk type HPV E6E7 gene sequence, the method designs ZFNs expression vectors of a targeted specific site to targetedly cut the HPVE6E7 gene sequence in cells, thereby knocking out a target gene. In corresponding subtype HPV infected cells, the ZFNs can significantly induce cell apoptosis and proliferation inhibition, and has no effect on other subtype HPV positive cells and HPV negative cells. Transfection of the ZFNs expression vectors in a subcutaneous tumor model of HPV positive cervical cancer cells can obviously inhibit the growth rate of subcutaneous tumors and alleviate tumors. The method for targeted knockout of the high-risk HPV E6E7 gene by ZFNs can efficiently destroy virus oncogenes at the DNA level so as to make HPV infected cells undergo apoptosis and proliferation inhibition, and has enormous treatment value to HPV infection related diseases, especially cervical intraepithelial neoplasias and other precancerous lesions.
Owner:WUHAN KDWS BIOLOGICAL TECH CO LTD
Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
InactiveUS20090053296A1BiocideOrganic active ingredientsCervical intraepithelial neoplasiaCervix Intraepithelial Neoplasia
The present invention concerns the use of E6 and / or E7 peptides from human papilloma virus (HPV) to evaluate a cell-mediated response in a patient infected with HPV to determine the prognosis for that patient with respect to the development or recurrence of pre-cancerous or cancerous growths, including cervical intraepithelial neoplasia (CIN).
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
In vitro culture method of cervical intraepithelial neoplasia cells
InactiveCN103602630AImprove survival rateHigh purityVertebrate cellsArtificial cell constructsHuman papillomavirusCulture fluid
The invention discloses an in vitro culture method of cervical intraepithelial neoplasia cells. The in vitro culture method comprises the following steps: step one, taking a small piece of human cervical neoplasia tissue; step two, after digesting and decomposing by a type I collagenase, preparing a cell suspension; step three, utilizing a trypan blue dye exclusion method to judge the cell activity; step four, introducing the cell suspension into a culture bottle containing a low fetal bovine serum culture medium and coated with rat tail collagen, and waiting for the cells to adhere to the wall; and step five, after the cells adhere to the wall, replacing with a serum-free culture medium, purifying the cervical intraepithelial neoplasia cells, replacing the culture liquid weekly for at least two times, and after the cells are fused to 80%-85%, carrying out passage. The CIN cells cultured by the method have high survival rate and high purity, allows the morphology of the cells after passage to have no obvious change compared with that of the primary cells, and is carried with human papillomavirus (HPV); and the success of the CIN cell in vitro culture provides technical support for research on treatment of cervical cancer.
Owner:刘玉珍
Application of tetramethylpyrazine to preparation of medicine for treating contrast-induced nephropathy
InactiveCN102552267AProtect kidney functionEffective in preventing and treating CINOrganic active ingredientsUrinary disorderNephrosisPharmaceutical drug
The invention relates to application of tetramethylpyrazine (TMP) to the preparation of a medicine for treating nephropathy. The nephropathy is contrast-induced nephropathy (CIN). The invention has the advantages that: novel use of a Chinese medicine monomer, namely the TMP is provided; the experimental result proves that the TMP can effectively protect the renal functions of cervical intraepithelial neoplasia (CIN) model rats, and has a good effect of preventing and treating CIN; the mechanism research discovers that the TMP can antagonize the apoptosis of a contrast agent, namely iohexol-induced rat renal tubular epithelial cells by inhibiting Caspase3; and the invention provides a novel therapeutic medicine for the CIN, and the novel therapeutic medicine has a good application prospect.
Owner:SHANGHAI HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Treatment of the reproductive tract with pulsed electric fields
Devices, systems and methods are provided for treating conditions of the reproductive tract. A number of conditions can afflict the lining and cell layers deeper within the anatomical structures. For example, cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is a condition involving abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer in situ (CIS). Other conditions include human papillomavirus (HPV)-related cervical disease, various endometrial diseases, acute and chronic cervicitis, and various infections (e.g. trichomoniasis) to name a few. In some embodiments, treatments eliminate diseased, damaged, abnormal or otherwise undesired cells leaving the tissue framework intact. This allows the tissue to regenerate in a normal fashion, avoiding the formation of scar tissue. When the tissue framework is left intact, the framework structure repopulates with healthy cells, regenerating the normal tissue without altering the structural properties.
Owner:GALVANIZE THERAPEUTICS INC
Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system
InactiveCN103096873AHeavy metal active ingredientsOrganic active ingredientsDiseaseHuman papillomavirus
A medical composition including a chemotherapeutic medication or a targeted therapy medication is used in a human female patient for the treatment of a disease selected in the group comprising cervical cancer, cervical intraepithelial neoplasia (CIN), human papillomavirus (HPV) infection of the female genital system; the chemotherapeutic agent or targeted therapy medication is locally delivered directly to cervix of a female genital system by an implanted medical device including a stem to be implanted in the cervix. The stem has a drug carrying layer including the medical composition. A process for the treatment of the above diseases is also disclosed.
Owner:IST NAZ PER LO STUDIO E LA CURA DEI TUMORI
Curcumin-containing pharmaceutical composition
InactiveCN103611076AClear ingredientsQuality is easy to controlHydroxy compound active ingredientsKetone active ingredientsLower riskCervical intraepithelial neoplasia
The invention belongs to the technical field of medicines and provides a curcumin-containing pharmaceutical composition containing curcumin, volatile oil of curcuma longa, turmerone, curcumol and borneol. The pharmaceutical composition is definite in component and controllable in quality, can be used for preparing a vaginal administration preparation, a rectal administration preparation or an oral mucosal administration preparation, has favorable treating or preventing effect for HR-HPV (High Risk-Human Pappilomavirus) or LR-HPV (Low Risk-Human Pappilomavirus), cervical diseases (cervical intraepithelial neoplasia and carcinoma of uterine cervix), vulvar cancer, anal carcinoma, rectal cancer, oral cancer, verruca acuminate, verruca vulgaris, verruca plana, verruca plantaris and the like and is suitable for wide clinic application.
Owner:明远药业有限公司
DNA methylation biomarkers for early detection of cervical cancer
PendingCN113423843AEasy to detectMicrobiological testing/measurementProteomicsDNA methylationHuman DNA sequencing
Owner:HKG EPITHERAPEUTICS LTD
Antigen and kit for detecting anti-human-papillomavirus antibody and application of antigen
InactiveCN103940993ARelieve painPrevent proliferationVirus peptidesDsDNA virusesOncogene ProteinsCervical intraepithelial neoplasia
The invention relates to human papillomavirus (HPV) oncogene protein as an antiagen for detecting an anti-human-papillomavirus antibody, and the antigen has an amino acid sequence shown as SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3. The invention also provides an immunodetection kit which comprises the antigen for detecting anti-HPV antibody. The invention also provides application of the antigen used for detecting anti-HPV antibody to detect anti-HPV antibody in human blood or saliva. The antigen used for detecting anti-HPV antibody is capable of detecting an HPV antibody in blood or saliva with high sensitivity and high specificity, and thus the antigen helps to provide basis for doctors to accurately diagnose patient cervical intraepithelial neoplasia and cervical carcinoma transformed from HPV virus oncogene, and the immunodetection kit prepared by employing the antigen is capable of rapidly simply accurately detecting the PHV antibody in blood or saliva and is suitable for large-scale popularization and application.
Owner:ATTOGEN BIOMEDICAL SUZHOU INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com